Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.

Check Now !

Moderate To Severe Plaque Psoriasis Pipeline Insight

DelveInsight’s, “Moderate To Severe Plaque Psoriasis - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Moderate To Severe Plaque Psoriasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

Moderate To Severe Plaque Psoriasis Understanding

Moderate To Severe Plaque Psoriasis : Overview

Psoriasis is a genetically determined, systemic, immune-mediated long-term inflammatory condition that affects the skin, nails and joints. When psoriasis affects more than 5 percent of your body, it’s considered moderate to severe. It may affect your genitals, face, hands, and feet. Biologic drugs are a popular treatment option for this type of psoriasis. Biologics may be used alone or with other treatments to ease your psoriasis. The doctor may assess the severity by looking at the physical symptoms of psoriasis. They may look for erythema (redness), scaling, and induration (lesion thickness). These three signs are often used to classify the severity of psoriasis.


"Moderate To Severe Plaque Psoriasis - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Moderate To Severe Plaque Psoriasis pipeline landscape is provided which includes the disease overview and Moderate To Severe Plaque Psoriasis treatment guidelines. The assessment part of the report embraces, in depth Moderate To Severe Plaque Psoriasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Moderate To Severe Plaque Psoriasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Moderate To Severe Plaque Psoriasis R&D. The therapies under development are focused on novel approaches to treat/improve Moderate To Severe Plaque Psoriasis .

Moderate To Severe Plaque Psoriasis Emerging Drugs Chapters

This segment of the Moderate To Severe Plaque Psoriasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Moderate To Severe Plaque Psoriasis Emerging Drugs


Roflumilast topical: Arcutis Biotherapeutics

Topical roflumilast cream (ARQ-151) is a small molecule inhibitor of phosphodiesterase type 4 (PDE4), an intracellular enzyme that increases the production of proinflammatory mediators and decreases production of anti-inflammatory mediators, and has been implicated in a wide range of inflammatory diseases including psoriasis. The drug is currently in phase 3 of clinical trials for the treatment of mild to moderate psoriasis.


CC-90006: AnaptysBio

AnaptysBio-generated anti-inflammatory antibody programs, and has initiated a Phase 1 trial for CC-90006, a PD-1 agonist antibody, which is indicated for psoriasis.

Further product details are provided in the report……..

Moderate To Severe Plaque Psoriasis : Therapeutic Assessment

This segment of the report provides insights about the different Moderate To Severe Plaque Psoriasis drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Moderate To Severe Plaque Psoriasis

There are approx. 4+ key companies which are developing the therapies for Moderate To Severe Plaque Psoriasis . The companies which have their Moderate To Severe Plaque Psoriasis drug candidates in the most advanced stage, i.e. phase III include, Acrutis Biotherapeutics Biopharma.

Phases

DelveInsight’s report covers around 4+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Moderate To Severe Plaque Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • intravitreal
  • Subretinal
  • Topical.
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Moderate To Severe Plaque Psoriasis : Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Moderate To Severe Plaque Psoriasis therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Moderate To Severe Plaque Psoriasis drugs.

Moderate To Severe Plaque Psoriasis Report Insights

  • Moderate To Severe Plaque Psoriasis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Moderate To Severe Plaque Psoriasis Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Moderate To Severe Plaque Psoriasis drugs?
  • How many Moderate To Severe Plaque Psoriasis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Moderate To Severe Plaque Psoriasis ?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Moderate To Severe Plaque Psoriasis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Moderate To Severe Plaque Psoriasis and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Moderate To Severe Plaque Psoriasis: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Moderate To Severe Plaque Psoriasis – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

  • Mild To Moderate Plaque Psoriasis companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Moderate To Severe Plaque Psoriasis Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

  • Comparative Analysis

Roflumilast topical: Acrutis Biotherapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

CC-90006: AnaptysBio

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Moderate To Severe Plaque Psoriasis Key Companies

Moderate To Severe Plaque Psoriasis Key Products

Moderate To Severe Plaque Psoriasis- Unmet Needs

Moderate To Severe Plaque Psoriasis- Market Drivers and Barriers

Moderate To Severe Plaque Psoriasis- Future Perspectives and Conclusion

Moderate To Severe Plaque Psoriasis Analyst Views

Moderate To Severe Plaque Psoriasis Key Companies

Appendix



List of Table

Table 1: Total Products for Moderate to Severe Plaque Psoriasis

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Moderate to Severe Plaque Psoriasis

Figure 2: Late Stage Products

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products

• Acrutis Biotherapeutics

• AnaptysBio

• Evelo Biosciences

Forward to Friend

Need A Quote